PARANEOPLASTIC SYNDROME side effect
What is PARANEOPLASTIC SYNDROME ?Drugs associated with PARANEOPLASTIC SYNDROME
BEVACIZUMAB CILOSTAZOL FEMARA FLUOROURACIL LARIAM LEUPROLIDE TARCEVA XYLOCAINEPARANEOPLASTIC SYNDROME : Bevacizumab Side Effects Report #5551383-0
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Dec 04, 2007. Male patient, weighting 159.0 lb, was diagnosed with colorectal cancer metastatic, colon cancer metastatic, atrial fibrillation, hypertension, dyspepsia and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: paraneoplastic syndrome, . BEVACIZUMAB dosage: 385.5 MG, Q2W. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, COUMADIN, COZAAR, CARDIZEM, PEPCID. Patient was hospitalized. Patient recovered.
PARANEOPLASTIC SYNDROME : Bevacizumab Side Effects Report #5475899-0
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Sept 21, 2007. Male patient, weighting 159.0 lb, was diagnosed with colorectal cancer metastatic, colon cancer metastatic, atrial fibrillation, hypertension, dyspepsia and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: paraneoplastic syndrome, . BEVACIZUMAB dosage: 385.5 MG, Q2W. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, LEUCOVORIN, COUMADIN, COZAAR, CARDIZEM, PEPCID. Patient was hospitalized. Patient recovered.
PARANEOPLASTIC SYNDROME : Bevacizumab Side Effects Report #5443545-8
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Aug 27, 2007. Male patient, weighting 159.0 lb, was diagnosed with colorectal cancer metastatic, atrial fibrillation, hypertension, dyspepsia and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: paraneoplastic syndrome, . BEVACIZUMAB dosage: 385.5 MG, Q2W. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, COUMADIN, COZAAR, CARDIZEM, PEPCID. Patient died on 07/31/2007.
PARANEOPLASTIC SYNDROME : Bevacizumab Side Effects Report #5444014-1
BEVACIZUMAB problem was reported by a Physician from UNITED STATES on Aug 28, 2007. Male patient was diagnosed with colorectal cancer and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: paraneoplastic syndrome, sepsis, . BEVACIZUMAB dosage: 1385.5 MG, Q2W. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, FOLINIC ACID, COUMADIN, COZAAR, CARDIZEM, PEPCID. Patient was hospitalized. Patient died on 07/31/2007.
PARANEOPLASTIC SYNDROME : Bevacizumab Side Effects Report #5467474-9
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Sept 14, 2007. Male patient, weighting 159.0 lb, was diagnosed with colorectal cancer metastatic, atrial fibrillation, hypertension, dyspepsia and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: paraneoplastic syndrome, sepsis, . BEVACIZUMAB dosage: 385.5 MG, Q2W. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, LEUCOVORIN, COUMADIN, COZAAR, CARDIZEM, PEPCID. Patient died on 07/31/2007.
PARANEOPLASTIC SYNDROME : Bevacizumab Side Effects Report #5413586-5
BEVACIZUMAB problem was reported by a Health Professional from UNITED STATES on Aug 06, 2007. Male patient, weighting 159.0 lb, was diagnosed with colorectal cancer metastatic, atrial fibrillation, hypertension, dyspepsia and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: paraneoplastic syndrome, sepsis, . BEVACIZUMAB dosage: 385.5 MG, Q2W. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, COUMADIN, COZAAR, CARDIZEM, PEPCID. Patient died on 07/31/2007.
PARANEOPLASTIC SYNDROME : Bevacizumab Side Effects Report #5420845-9
Health Professional from UNITED STATES reported BEVACIZUMAB problem on Aug 10, 2007. Male patient, weighting 159.0 lb, was diagnosed with colorectal cancer metastatic, atrial fibrillation, hypertension, dyspepsia and was treated with BEVACIZUMAB. After drug was administered, patient experienced the following problems/side effects: paraneoplastic syndrome, . BEVACIZUMAB dosage: 385.5 MG, Q2W. During the same period patient was treated with OXALIPLATIN, FLUOROURACIL, LEUCOVORIN CALCIUM, COUMADIN, COZAAR, CARDIZEM, PEPCID. Patient died on 07/31/2007.
PARANEOPLASTIC SYNDROME : Xylocaine Side Effects Report #5612550-0
XYLOCAINE problem was reported by a Health Professional from FRANCE on Jan 31, 2008. Male patient, 79 years of age, was diagnosed with lung disorder, ischaemic cardiomyopathy and was treated with XYLOCAINE. After drug was administered, patient experienced the following problems/side effects: dermatitis bullous, paraneoplastic syndrome, rash macular, serratia infection, skin exfoliation, . XYLOCAINE dosage: unknown. During the same period patient was treated with CARBOCAINE, DIPRIVAN, PROFENID, PERFALGAN, AUGMENTIN, CIFLOX, OFLOCET, LASILIX. Patient was hospitalized. Patient recovered.
PARANEOPLASTIC SYNDROME : Tarceva Side Effects Report #5619233-1
Physician from TAIWAN, PROVINCE OF CHINA reported TARCEVA problem on Jan 22, 2008. Female patient was diagnosed with lung adenocarcinoma and was treated with TARCEVA. After drug was administered, patient experienced the following problems/side effects: hirsutism, paraneoplastic syndrome, rash, . TARCEVA dosage: unknown. Patient recovered.
PARANEOPLASTIC SYNDROME : Leuprolide Side Effects Report #5569743-0
LEUPROLIDE ACETATE problem was reported by a Consumer or non-health professional from AUSTRIA on Dec 14, 2007. Male patient, 73 years of age, was diagnosed with neoplasm prostate and was treated with LEUPROLIDE ACETATE. After drug was administered, patient experienced the following problems/side effects: cushing's syndrome, paraneoplastic syndrome, . LEUPROLIDE ACETATE dosage: 11.25 MG (11.25 MG, 1 IN 3 M) SUBCUTANEOUS. During the same period patient was treated with BISOPROLOL, MARCUMAR, DEFLAMAT, ZOMETA. Patient was hospitalized. Patient recovered.
PARANEOPLASTIC SYNDROME : Femara Side Effects Report #5465852-5
Consumer or non-health professional from UNITED STATES reported FEMARA problem on Sept 13, 2007. Female patient was diagnosed with breast cancer and was treated with FEMARA. After drug was administered, patient experienced the following problems/side effects: erythema, paraneoplastic syndrome, polyarthritis, swelling, . FEMARA dosage: 2.5 MG, QD. Patient was hospitalized. Patient recovered.
PARANEOPLASTIC SYNDROME : Lariam Side Effects Report #5382114-5
LARIAM problem was reported by a Health Professional from UNITED STATES on June 27, 2007. Female patient, 51 years of age, was diagnosed with malaria prophylaxis and was treated with LARIAM. After drug was administered, patient experienced the following problems/side effects: amyotrophic lateral sclerosis, paraneoplastic syndrome, . LARIAM dosage: unknown. During the same period patient was treated with RILUTEK, VITAMIN E, ASCORBIC ACID, VITAMINS NOS, COENZYME Q, ALPHA LIPOIC ACID. Patient was hospitalized. Patient recovered.
PARANEOPLASTIC SYNDROME : Cilostazol Side Effects Report #5403551-6
Consumer or non-health professional from JAPAN reported CILOSTAZOL problem on July 17, 2007. Male patient, 74 years of age, was diagnosed with shunt occlusion and was treated with CILOSTAZOL. After drug was administered, patient experienced the following problems/side effects: megakaryocytes decreased, paraneoplastic syndrome, platelet count decreased, pleural effusion, . CILOSTAZOL dosage: 100 MG. During the same period patient was treated with SEVELAMER HYDROCHLORIDE, PRECIPITATED CALCIUM CARBONATE, HAEMODIALYSIS. Patient recovered.
PARANEOPLASTIC SYNDROME : Lariam Side Effects Report #5382114-5
LARIAM problem was reported by a Health Professional from UNITED STATES on June 27, 2007. Female patient, 51 years of age, was diagnosed with malaria prophylaxis and was treated with LARIAM. After drug was administered, patient experienced the following problems/side effects: amyotrophic lateral sclerosis, paraneoplastic syndrome, . LARIAM dosage: unknown. During the same period patient was treated with RILUTEK, VITAMIN E, ASCORBIC ACID, VITAMINS NOS, COENZYME Q, ALPHA LIPOIC ACID. Patient was hospitalized. Patient recovered.
PARANEOPLASTIC SYNDROME : Cilostazol Side Effects Report #5403551-6
Consumer or non-health professional from JAPAN reported CILOSTAZOL problem on July 17, 2007. Male patient, 74 years of age, was diagnosed with shunt occlusion and was treated with CILOSTAZOL. After drug was administered, patient experienced the following problems/side effects: megakaryocytes decreased, paraneoplastic syndrome, platelet count decreased, pleural effusion, . CILOSTAZOL dosage: 100 MG. During the same period patient was treated with SEVELAMER HYDROCHLORIDE, PRECIPITATED CALCIUM CARBONATE, HAEMODIALYSIS. Patient recovered.
PARANEOPLASTIC SYNDROME : Fluorouracil Side Effects Report #5425848-6
FLUOROURACIL problem was reported by a Health Professional from UNITED STATES on Aug 13, 2007. Male patient, 82 years of age, was diagnosed with colorectal cancer metastatic and was treated with FLUOROURACIL. After drug was administered, patient experienced the following problems/side effects: anaemia, dehydration, paraneoplastic syndrome, sepsis, stomatitis, . FLUOROURACIL dosage: 1800 MILLIGRAM/SQ. METER 2 WEEK, INTRAVENOUS DRIP. During the same period patient was treated with FOLINIC ACID, OXALIPLATIN, BEVACIZUMAB, WARFARIN, LOSARTAN POTASSIUM, DILTIAZEM, FAMOTIDINE, DIGOXIN. Patient was hospitalized. Patient died on 07/31/2007.